| Ident. | Authors (with country if any) | Title |
|---|
| 000415 (2011) |
Tsutomu Takeuchi [Japon] ; Yoshiya Tanaka ; Koichi Amano ; Daisuke Hoshi ; Masao Nawata ; Hayato Nagasawa ; Eri Sato ; Kazuyoshi Saito ; Yuko Kaneko ; Shunsuke Fukuyo ; Takahiko Kurasawa ; Kentaro Hanami ; Hideto Kameda ; Hisashi Yamanaka | Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study. |
| 000951 (2014) |
Yoshiya Tanaka [Japon] ; Tsutomu Takeuchi ; Koichi Amano ; Kazuyoshi Saito ; Kentaro Hanami ; Masao Nawata ; Shunsuke Fukuyo ; Hideto Kameda ; Yuko Kaneko ; Takahiko Kurasawa ; Hayato Nagasawa ; Daisuke Hoshi ; Eri Sato ; Hisashi Yamanaka | Effect of interleukin-6 receptor inhibitor, tocilizumab, in preventing joint destruction in patients with rheumatoid arthritis showing inadequate response to TNF inhibitors. |
| 000A70 (2015) |
Keisuke Izumi [Japon] ; Yuko Kaneko ; Hidekata Yasuoka ; Noriyuki Seta ; Hideto Kameda ; Masataka Kuwana ; Tsutomu Takeuchi | Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52. |
| 000C57 (2015) |
Naoshi Nishina [Japon] ; Yuko Kaneko ; Hideto Kameda ; Tsutomu Takeuchi | The effect of tocilizumab on preventing relapses in adult-onset Still's disease: A retrospective, single-center study. |
| 000D12 (2015) |
Jun Kikuchi [Japon] ; Misato Hashizume [Japon] ; Yuko Kaneko [Japon] ; Keiko Yoshimoto [Japon] ; Naoshi Nishina [Japon] ; Tsutomu Takeuchi [Japon] | Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response. |
| 001019 (2015) |
Keisuke Izumi [Japon] ; Yuko Kaneko [Japon] ; Misato Hashizume [Japon] ; Keiko Yoshimoto [Japon] ; Tsutomu Takeuchi [Japon] | Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study). |
| 001031 (2016) |
Yuko Kaneko [Japon] ; Tatsuya Atsumi [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekata Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Hayato Nagasawa [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Tsutomu Takeuchi [Japon] | Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). |
| 001104 (2016) |
Mitsuhiro Akiyama [Japon] ; Yuko Kaneko [Japon] ; Harumi Kondo [Japon] ; Tsutomu Takeuchi [Japon] | Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis. |
| 001111 (2016) |
Keisuke Izumi ; Yuko Kaneko ; Misato Hashizume ; Keiko Yoshimoto ; Tsutomu Takeuchi | Correction: Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study). |
| 001138 (2016) |
Mitsuhiro Akiyama [Japon] ; Yuko Kaneko [Japon] ; Kunihiro Yamaoka [Japon] ; Harumi Kondo [Japon] ; Tsutomu Takeuchi [Japon] | Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study. |
| 001224 (2016) |
Yuko Kaneko ; Tsutomu Takeuchi | [IL-6 blockade]. |
| 001514 (2017) |
Shuntaro Saito [Japon] ; Yuko Kaneko [Japon] ; Keisuke Izumi [Japon] ; Tsutomu Takeuchi [Japon] | Utility of Dose Frequency Adjustment in Tocilizumab Administration for Rheumatoid Arthritis. |
| 001785 (2017) |
Shuntaro Saito [Japon] ; Katsuya Suzuki [Japon] ; Keiko Yoshimoto [Japon] ; Yuko Kaneko [Japon] ; Yoshihiro Matsumoto [Japon] ; Kunihiro Yamaoka [Japon] ; Tsutomu Takeuchi [Japon] | A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis. |
| 001A81 (2018) |
Yuko Kaneko [Japon] ; Masaru Kato [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekara Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Tsutomu Takeuchi [Japon] | Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). |
| 001B41 (2018) |
Yoshiya Tanaka [Japon] ; Hideto Kameda [Japon] ; Kazuyoshi Saito [Japon] ; Yuko Kaneko [Japon] ; Eiichi Tanaka [Japon] ; Shinsuke Yasuda [Japon] ; Naoto Tamura [Japon] ; Keishi Fujio [Japon] ; Takao Fujii [Japon] ; Toshihisa Kojima [Japon] ; Tatsuhiko Anzai [Japon] ; Chikuma Hamada [Japon] ; Yoshihisa Fujino [Japon] ; Shinya Matsuda [Japon] ; Hitoshi Kohsaka [Japon] | Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study. |
| 001C29 (2018) |
Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonoti Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon] | Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. |
| 001C76 (2019) |
Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonori Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon] | Response to: 'Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment' by Lee. |
| 001D22 (2020) |
Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonori Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon] | Response to: 'Some concerns from Turkey' by Bilgin et al. |
| 001F59 (2019) |
Masaru Kato [Japon] ; Yuko Kaneko [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekata Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Hayato Nagasawa [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Isao Yokota [Japon] ; Tatsuya Atsumi [Japon] ; Tsutomu Takeuchi [Japon] | Predictive value of serum amyloid a levels for requirement of concomitant methotrexate in tocilizumab initiation: A post hoc analysis of the SURPRISE study. |
| 002349 (2020) |
Hiroki Yamada [Japon] ; Yuko Kaneko [Japon] ; Hiroya Tamai [Japon] ; Tsutomu Takeuchi [Japon] | Biomarkers for disease flare in patients with adult-onset Still's disease undergoing treatment with tocilizumab. |
| 002756 (2020) |
Yoshiya Tanaka [Japon] ; Hideto Kameda [Japon] ; Kazuyoshi Saito [Japon] ; Yuko Kaneko [Japon] ; Eiichi Tanaka [Japon] ; Shinsuke Yasuda [Japon] ; Naoto Tamura [Japon] ; Keishi Fujio [Japon] ; Takao Fujii [Japon] ; Toshihisa Kojima [Japon] ; Tatsuhiko Anzai [Japon] ; Chikuma Hamada [Japon] ; Yoshihisa Fujino [Japon] ; Shinya Matsuda [Japon] ; Hitoshi Kohsaka [Japon] | Response to tocilizumab and work productivity in patients with rheumatoid arthritis: 2-year follow-up of FIRST ACT-SC study. |
